Cui Lifeng, Shu Chang, Liu Zitao, Tong Weihua, Cui Miao, Wei Chengguo, Tang Jian Jenny, Liu Xiufen, Hai Hujing, Jiang Jing, He Jin, Zhang David Y, Ye Fei, Li Yulin
Department of Pathology, College of Basic Medical Sciences of Jilin University, Changchun, Jilin 130021, China.
Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Pregnancy Hypertens. 2018 Oct;14:279-285. doi: 10.1016/j.preghy.2018.01.009. Epub 2018 Feb 1.
Preeclampsia is a multi-system disorder in pregnancy which has no effective treatment. The diagnosis of preeclampsia is based on clinical presentation and routine laboratory tests.
This study aimed at identifying serum protein markers for diagnosis of preeclampsia and predicting its severe features.
In total, 172 pregnant women were enrolled in this study including 110 subjects with preeclampsia and 62 normotensive subjects. Eleven serum proteins (VEGF, sFlt-1, sEndoglin, PlGF, sEGFR, prolactin, PTX3, PAI-1, NGAL, IL-27, COX-2) were assessed using Luminex multiplex immunoassay and ELISA.
The levels of seven proteins (sFlt-1, VEGF, sEndoglin, sEGFR, PlGF, NGAL, COX-2) correlated with preeclampsia, and 4 proteins (VEGF, sEndoglin, PlGF, sEGFR) were identified as independent factors associated with preeclampsia. The levels of three proteins (sEndoglin, PTX3, sFlt-1) correlated with severe features of preeclampsia, and three variables (serum creatinine, platelet count and sEndoglin) were identified as independent factors in predicting severe features of preeclampsia.
A combination of serum protein markers (VEGF, sEndoglin, PlGF, sEGFR) and clinical variables (serum creatinine, platelet count and sEndoglin) could be used as analytical tool in diagnosis of preeclampsia and its severe features, respectively. Serum sEGFR, a novel biomarker in preeclampsia, may be involved in the pathogenesis of preeclampsia.
子痫前期是妊娠期的一种多系统疾病，尚无有效治疗方法。子痫前期的诊断基于临床表现和常规实验室检查。
本研究旨在确定用于诊断子痫前期并预测其严重特征的血清蛋白标志物。
本研究共纳入172名孕妇，其中110名为子痫前期患者，62名为血压正常的受试者。使用Luminex多重免疫测定法和酶联免疫吸附测定法评估了11种血清蛋白（血管内皮生长因子、可溶性血管内皮生长因子受体-1、可溶性内皮糖蛋白、胎盘生长因子、可溶性表皮生长因子受体、催乳素、3型 pentraxin、纤溶酶原激活物抑制剂-1、中性粒细胞明胶酶相关脂质运载蛋白、白细胞介素-27、环氧化酶-2）。
7种蛋白（可溶性血管内皮生长因子受体-1、血管内皮生长因子、可溶性内皮糖蛋白、可溶性表皮生长因子受体、胎盘生长因子、中性粒细胞明胶酶相关脂质运载蛋白、环氧化酶-2）的水平与子痫前期相关，4种蛋白（血管内皮生长因子、可溶性内皮糖蛋白、胎盘生长因子、可溶性表皮生长因子受体）被确定为与子痫前期相关的独立因素。3种蛋白（可溶性内皮糖蛋白、3型 pentraxin、可溶性血管内皮生长因子受体-1）的水平与子痫前期的严重特征相关，3个变量（血清肌酐、血小板计数和可溶性内皮糖蛋白）被确定为预测子痫前期严重特征的独立因素。
血清蛋白标志物（血管内皮生长因子、可溶性内皮糖蛋白、胎盘生长因子、可溶性表皮生长因子受体）和临床变量（血清肌酐、血小板计数和可溶性内皮糖蛋白）的组合可分别用作诊断子痫前期及其严重特征的分析工具。血清可溶性表皮生长因子受体是子痫前期的一种新型生物标志物，可能参与子痫前期的发病机制。
